Amanta Healthcare, a pharmaceutical company specializing in sterile liquid products, has refiled its offer papers with the Securities and Exchange Board of India (SEBI) as of 3 February 2025. The move follows the withdrawal of its earlier IPO application on 31 December 2024. Beeline Capital Advisors has been appointed as the book-running lead manager, while MUFG Intime India (formerly Link Intime India) serves as the registrar for the issue. This refiling signals the company’s firm intent to enter the public market and scale its operations.

Amanta Healthcare – Company Overview
Amanta Healthcare develops, manufactures, and markets sterile liquid products, including large-volume parenterals (LVPs) and small-volume parenterals (SVPs). It employs advanced technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) to ensure product quality. The company’s portfolio covers six therapeutic segments:
- Fluid therapy (IV fluids)
- Formulations
- Diluents and injectables
- Ophthalmic solutions
- Respiratory care
- Irrigation solutions
Additionally, Amanta produces medical devices, including first-aid solutions and eye lubricants. Its product packaging ranges from 2 ml to 1,000 ml, catering to diverse market needs both domestically and internationally.
The company operates a manufacturing facility in Hariyala, Gujarat, with four LVP production lines and three SVP lines. These facilities comply with global Good Manufacturing Practices (GMP) standards, allowing Amanta Healthcare to manufacture products across multiple therapeutic categories, including:
- Quinolones
- Antibiotics
- Antifungals
- Diuretics
- Anti-anaerobics
- Ophthalmic and respiratory solutions
Amanta continuously invests in facility upgrades to enhance efficiency, improve quality, and expand production capacity.
Market Presence
Amanta Healthcare operates through three key business segments:
- National Sales – Over 45 branded products distributed through 316+ stockists and distributors across India.
- International Sales – Presence in 19 countries, including Africa, Latin America, and the UK.
- Product Partnering – Manufacturing for third-party pharmaceutical companies under contract agreements.
As of 31 December 2024, the company had 47 products registered across 112 international jurisdictions, reinforcing its compliance and credibility with regulatory agencies worldwide.
Financial Performance
Amanta Healthcare has demonstrated a steady growth in total income over the years. For the first nine months of FY25, the company reported a total income of INR 203.87 crore, following INR 281.61 crore in FY24, INR 262.70 crore in FY23, and INR 226.27 crore in FY22. However, its profitability has been inconsistent.
The company posted a profit after tax (PAT) of INR 4.54 crore in 9M FY25, up from INR 3.63 crore in FY24. In contrast, FY23 saw a significant loss of INR 211.06 crore, whereas FY22 recorded a healthy profit of INR 53.88 crore. Despite these fluctuations, the company has managed to recover from the FY23 setback and return to profitability in FY24, indicating improved financial stability.
Utilization of IPO Proceeds
Amanta Healthcare is planning to use the IPO proceeds for the following purposes:
- INR 70.00 crore – New SteriPort manufacturing line in Hariyala, Gujarat.
- INR 30.13 crore – New SVP manufacturing line at the same location.
- General corporate purposes – Amount subject to final issue pricing.
The company aims to use these funds to strengthen its infrastructure, increase production capacity, and expand its market reach.
Promoters and Management
Amanta Healthcare is promoted by Bhavesh Patel, Vishal Patel, Jayshreeben Patel, Jitendrakumar Patel, and Milcent Appliances. The company is led by Managing Director Bhavesh Patel, supported by an experienced leadership team with extensive industry expertise.

Conclusion
Amanta Healthcare’s IPO refiling underscores its commitment to expanding operations and strengthening market positioning. The company plans to deploy funds into capacity building and infrastructure enhancements. With a strong regulatory track record and international presence, Amanta is positioned for sustainable growth.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central.